Phase IV O2 Consumption Study in COPD Patients.

Exclusion Criteria

• •1. Subject is an employee or relative of an employee involved in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
• •2. Previous enrollment or randomization in this study.
• •3. Participation in another clinical study with an investigational product (IP) during the last 30 days prior to Screening (Visit 1).
• •4. Subjects who are unable to discontinue their regular chronic COPD medications (including LAMAs and/or LABA/ICS) and/or who are unable or unwilling to comply with study requirements.
• •5. Subjects who are taking uLABAs (indacaterol, vilanterol) or uLABA-containing products.
• •6. Subjects who are taking PDE-4 inhibitors (roflumilast).
• •7. Subjects who are taking oral corticosteroids on a chronic, regular basis.
• •8. Subjects using daytime oxygen therapy.
• •9. Subjects who are currently pregnant (confirmed with positive pregnancy test) or breast feeding.
• •10. History of respiratory tract infection (including the upper respiratory tract) and/or pulmonary exacerbation within 6 weeks prior to Screening (Visit 1).
• •11. Pulmonary resection or lung volume reduction surgery within 12 months prior to Screening (Visit 1), or history of lung transplantation, or, in the Investigator's opinion, the subject may need thoracotomy or other lung surgery during the study.
• •12. History or current diagnosis of asthma and/or alpha 1 anti-trypsin deficiency.
• •13. Known active tuberculosis.
• •14. History of interstitial lung or massive pulmonary thromboembolic disease.
• •15. History of bronchiectasis secondary to respiratory diseases other than COPD (eg, cystic fibrosis, Kartagener's syndrome, etc).
• •16. Any clinically significant disease or disorder (eg, cardiovascular, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, psychiatric, major physical impairment) which, in the opinion of the Investigator, may put the subject at risk because of participation in the study, may influence the results of the study, or may affect the subject's ability to participate in the study.
• •17. Recent (within 12 months prior to Screening \[Visit 1\]) history of myocardial infarction, recent history of heart failure (New York Heart Association \[NYHA\] class III and IV, pulmonary edema, and/or cardiac arrhythmia.
• •18. Previous or current history of lung cancer.
• •19. History of cancer (within 5 years prior to Visit 1), except for non-metastatic, non melanoma skin cancer.
• •20. Subjects who cannot perform spirometry manuevers or tolerate body plethysmography.
• •21. Subjects with known hypersensitivity to Symbicort, its monocomponents (budesonide or formoterol), or its excipients.